About

Owen Haskins, Managing Editor, Bariatric News

Latest posts

COVID-19 pandemic could exacerbate childhood obesity

Public health scientists predict that school closures due to the COVID-19 pandemic will exacerbate the epidemic of childhood obesity in the US, according to researchers at Columbia University Mailman School of Public Health. Dr Andrew Rundle, associate professor of epidemiology at and colleagues, expect that COVID-19-related school closures will double out-of-school time this year for many children in the US and will exacerbate risk factors for weight gain associated with summer recess.

Majority of internists-in-training feel ill-equipped to treat obesity

Most resident physicians training in internal medicine do not feel adequately prepared to manage obesity in their patients, according to the results of a survey from Stanford University researchers. The results were accepted for presentation at ENDO 2020 (the Endocrine Society's annual meeting that was cancelled due to the COVIUD-19 pandemic) and will be published in a special supplemental section of the Journal of the Endocrine Society.

Bariatric surgery may be effective treatment for NAFLD

Bariatric surgery may be an effective treatment for non-alcoholic fatty liver disease (NAFLD), according to Portuguese research that was accepted for presentation at ENDO 2020 (the Endocrine Society's annual meeting that was cancelled due to the COVIUD-19 pandemic) and will be published in a special supplemental section of the Journal of the Endocrine Society.

DMR improves blood glucose levels, liver metabolic health in T2DM patients

Patients with poorly controlled type 2 diabetes who received Revita duodenal mucosal resurfacing (DMR) had significantly improved blood glucose levels, liver insulin sensitivity and other metabolic measures three months later, according to new data from the REVITA-2 study. These results, from a mixed meal tolerance test, have helped researchers verify the insulin sensitising mechanism by which hydrothermal ablation of the duodenum improves blood glucose levels in patients with type 2 diabetes.

Dasiglucagon effective in preventing post-gastric bypass hypoglycaemia

Zealand Pharma, a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has announced positive topline results from a Phase 2 clinical trial using mini-doses of dasiglucagon in individuals who have undergone gastric bypass bariatric surgery.

DMR improves blood glucose levels, liver metabolic health in T2DM patients

Patients with poorly controlled type 2 diabetes who received Revita duodenal mucosal resurfacing (DMR) had significantly improved blood glucose levels, liver insulin sensitivity and other metabolic measures three months later, according to new data from the REVITA-2 study. These results, from a mixed meal tolerance test, have helped researchers verify the insulin sensitising mechanism by which hydrothermal ablation of the duodenum improves blood glucose levels in patients with type 2 diabetes.

Dasiglucagon effective in preventing post-gastric bypass hypoglycaemia

Zealand Pharma, a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has announced positive topline results from a Phase 2 clinical trial using mini-doses of dasiglucagon in individuals who have undergone gastric bypass bariatric surgery.